Aptus Capital Advisors LLC Has $398,000 Holdings in Novartis AG (NYSE:NVS)

Aptus Capital Advisors LLC increased its position in Novartis AG (NYSE:NVSFree Report) by 16.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,125 shares of the company’s stock after buying an additional 579 shares during the period. Aptus Capital Advisors LLC’s holdings in Novartis were worth $398,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Syon Capital LLC bought a new stake in shares of Novartis during the third quarter valued at approximately $6,568,000. B. Riley Wealth Advisors Inc. increased its stake in Novartis by 7.0% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 28,024 shares of the company’s stock valued at $2,828,000 after purchasing an additional 1,833 shares in the last quarter. Global Retirement Partners LLC raised its holdings in Novartis by 3.4% during the third quarter. Global Retirement Partners LLC now owns 4,544 shares of the company’s stock worth $437,000 after buying an additional 150 shares during the last quarter. RFP Financial Group LLC lifted its stake in shares of Novartis by 308.9% in the second quarter. RFP Financial Group LLC now owns 3,177 shares of the company’s stock valued at $321,000 after buying an additional 2,400 shares in the last quarter. Finally, Cetera Advisor Networks LLC grew its holdings in shares of Novartis by 10.3% during the second quarter. Cetera Advisor Networks LLC now owns 68,805 shares of the company’s stock valued at $6,943,000 after buying an additional 6,451 shares during the last quarter. 7.00% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

NVS has been the topic of several recent research reports. Morgan Stanley started coverage on shares of Novartis in a research report on Tuesday, January 23rd. They issued an “equal weight” rating and a $114.00 price target on the stock. StockNews.com started coverage on Novartis in a research note on Wednesday, December 6th. They set a “strong-buy” rating on the stock. Finally, HSBC lowered shares of Novartis from a “buy” rating to a “hold” rating in a research note on Monday, December 18th.

Check Out Our Latest Research Report on NVS

Novartis Price Performance

Shares of NYSE NVS opened at $101.03 on Friday. The company has a market capitalization of $214.14 billion, a PE ratio of 14.07, a PEG ratio of 1.56 and a beta of 0.56. The company has a quick ratio of 0.93, a current ratio of 1.15 and a debt-to-equity ratio of 0.39. The stock’s 50 day moving average price is $102.77 and its 200-day moving average price is $100.30. Novartis AG has a twelve month low of $79.98 and a twelve month high of $108.78.

Novartis (NYSE:NVSGet Free Report) last issued its quarterly earnings results on Tuesday, January 30th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). The business had revenue of $11.42 billion for the quarter, compared to the consensus estimate of $11.69 billion. Novartis had a return on equity of 29.90% and a net margin of 29.83%. During the same quarter last year, the business posted $1.51 earnings per share. On average, equities analysts anticipate that Novartis AG will post 7.19 EPS for the current year.

Novartis Profile

(Free Report)

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. It offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

Featured Articles

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.